MedPath

Cabergoline

Generic Name
Cabergoline
Brand Names
Dostinex
Drug Type
Small Molecule
Chemical Formula
C26H37N5O2
CAS Number
81409-90-7
Unique Ingredient Identifier
LL60K9J05T
Background

Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.

Indication

For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.

Associated Conditions
Hyperprolactinemia, Idiopathic hyperprolactinemic disorder
Associated Therapies
Inhibition of physiological lactation
Clinical Trials
Related News

Satisfaction of Patients With the Chosen Method of Inhibition of Lactation

Not Applicable
Conditions
Lactation Suppressed
Interventions
Other: Natural methods
First Posted Date
2019-07-31
Last Posted Date
2019-07-31
Lead Sponsor
Żelazna Medical Centre, LLC
Target Recruit Count
90
Registration Number
NCT04038749
Locations
🇵🇱

Żelazna Medical Centre, Warsaw, Poland

Cabergoline for the Treatment of Chronic Pain Due to Endometriosis

Phase 2
Recruiting
Conditions
Endometriosis
Interventions
Drug: Placebo - Cap
First Posted Date
2019-04-26
Last Posted Date
2025-03-21
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
140
Registration Number
NCT03928288
Locations
🇺🇸

Standford University, Palo Alto, California, United States

🇺🇸

Childrens Hospital Colorado, Aurora, Colorado, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility

Phase 2
Conditions
Infertility
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2018-06-08
Last Posted Date
2018-06-08
Lead Sponsor
Assiut University
Target Recruit Count
120
Registration Number
NCT03549741

Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention

Phase 3
Completed
Conditions
Ovarian Hyperstimulation
Interventions
First Posted Date
2018-03-22
Last Posted Date
2018-03-29
Lead Sponsor
Benha University
Target Recruit Count
230
Registration Number
NCT03473613
Locations
🇪🇬

Ashraf nassif Elmantwe, Cairo, Elqalopia, Egypt

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Not Applicable
Recruiting
Conditions
Pituitary Adenoma
Pituitary Tumor
Recurrence Tumor
Prolactinoma
Interventions
First Posted Date
2018-03-07
Last Posted Date
2020-03-18
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
68
Registration Number
NCT03457389
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Phase 3
Conditions
Diabetes
Interventions
First Posted Date
2017-10-18
Last Posted Date
2018-08-27
Lead Sponsor
Sherief Abd-Elsalam
Target Recruit Count
60
Registration Number
NCT03313661
Locations
🇪🇬

Sherief Abd-Elsalam, Cairo, Egypt

Cabergoline in Nonfunctioning Pituitary Adenomas

Phase 3
Completed
Conditions
Nonfunctioning Pituitary Adenoma
Pituitary Adenoma
Interventions
First Posted Date
2017-09-05
Last Posted Date
2017-09-07
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
140
Registration Number
NCT03271918
Locations
🇧🇷

Laboratorio de Investigacoes Medicas 25, São Paulo, SP, Brazil

Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol

Phase 4
Conditions
Invitro Fertilization
Interventions
First Posted Date
2017-08-28
Last Posted Date
2017-08-28
Lead Sponsor
Cairo University
Target Recruit Count
120
Registration Number
NCT03263299
Locations
🇪🇬

Kasr Alainy medical school, Cairo, Egypt

Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome

Phase 2
Completed
Conditions
OHSS
Interventions
First Posted Date
2016-08-23
Last Posted Date
2018-12-27
Lead Sponsor
Aljazeera Hospital
Target Recruit Count
170
Registration Number
NCT02875587
Locations
🇪🇬

Aljazeera hospital, Giza, Egypt

🇪🇬

Riyadh Fertility and Reproductive Health center, Giza, Egypt

Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome

Phase 2
Conditions
Female Reproductive Problem
Interventions
Other: Placebo
First Posted Date
2015-12-31
Last Posted Date
2016-06-29
Lead Sponsor
Woman's Health University Hospital, Egypt
Target Recruit Count
88
Registration Number
NCT02644304
Locations
🇪🇬

Assiut university, Assiut, Egypt

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy